In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Sacubitril-valsartan treatment furtherly improves response to intermittent parenteral levosimendan in ambulatory patients with advanced heart failure with reduced ejection fraction

Session Poster Session 3

Speaker Benjamin Munoz Calvo

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : B Munoz Calvo (Alcala de Henares,ES), C Ganan-Gomez (Alcala de Henares,ES), A Quiles-Recuenco (Alcala de Henares,ES), B Calvo-Llorente (Alcala de Henares,ES), I Mendo-Pedrajas (Alcala de Henares,ES), J Navarro-Lopez (Alcala de Henares,ES), F Roman-Garcia (Alcala de Henares,ES)

B Munoz Calvo1 , C Ganan-Gomez1 , A Quiles-Recuenco1 , B Calvo-Llorente1 , I Mendo-Pedrajas1 , J Navarro-Lopez1 , F Roman-Garcia1 , 1Hospital Universitario Príncipe de Asturias - Alcala de Henares - Spain ,


BACKGROUND: : Intravenous intermittent administration of levosimendan (IALEVO) to ambulatory patients with advanced chronic heart failure (ACHF) with severely reduced  (< 35%)  ejection fraction (EF) has been shown  in several randomized trials (LAICA, LION-HEART, Levo-Rep) to improve their clinical status and to reduce NT-proBNP plasma levels and rehospitalizations. However, recruitment of patients in these trials were conducted in the pre-ARNI era, so the impact of simultaneous treatment with sacubitril-valsartan (SAV) on IALEVO strategy is unknown.
AIMS: To assess whether SAV treatment may affect the results of IALEVO in patients with ACHF.
METHODS AND RESULTS: we conducted an observational, non-randomized study on 36 patients with ACHF of a similar profile with SAV treatment for at least the previous 12 months.  Patients were randomly assigned at a 1:1 ratio to IALEVO or non-intervention groups; those receiving IALEVO were given a 6-hour intravenous infusion (0.2 µg/kg/min without bolus) every 2 weeks for 12 weeks. The primary endpoint was the effect on serum concentrations of NT-proBNP throughout the treatment period. Secondary endpoints included evaluation of 18-months rehospitalizations due to HF decompensation and score at the Kansas City Cardiomyopathy test. The area under the curve of the levels of NT-proBNP for patients who received IALEVO was significantly lower than for the non-intervened group (259 × 103 [95% Confidence Interval (CI) 189 × 103-395 × 103] vs. 328 × 103 [240 × 103-517 × 103], p = 0.004). In comparison with non-intervened group, the patients on IALEVO experienced a reduction in the rate of heart failure hospitalisation (hazard ratio 0.20; 95% CI 0.10–0.49; P = 0.001). Patients on IALEVO were less likely to experience a significant reduction in KCC score (P = 0.04). Adverse effects were similar in both groups. 
Conclusions:  In this small non-randomized, non controlled study, IALEVO to ambulatory patients with ACHF with EF < 35% already treated with SAV reduced plasma concentrations of NT-proBNP and hospitalization for HF decompensation. As with other patients in the pre-ARNI era, IALEVO seems to furtherly improve clinical and functional benefits provided by SAV in ACHF.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are